A randomized phase II trial of sunitinib administered daily for 4 weeks, followed by 2-week rest vs. 2-week on and 1-week off in metastatic renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 05 Dec 2011 Planned number of patients changed from 72 to 80 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Planned end Ddte changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.